Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous trastuzumab administered at home with single injection device in HER2-positive early breast cancer
2013-000829-31Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of trastuzumab in breast cancer, sponsored by Roche. Primary endpoint: Overall safety and tolerability of subcutaneous trastuzumab. Started Sep 2013; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-000829-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000829-31.